Xpa and Xpa/p53+/- Knockout Mice: Overview of Available Data

Abstract

DNA repair defi cient Xpa-/- and Xpa-/- /p53 +/- knock-out mice in a C57BL/6 genetic background, referred to as respectively the XPA and XPA/p53 model, were investigatedinthe international collaborative research program coordinated by InternationalLife Sciences Institute(ILSI)/Health and Environmental Science Institute. From the selected list of 21 ILSI compounds, 13 were tested in the XPA model, and 10 in the XPA/p53 model. With one exception, all studies had a duration of 9 months (39 weeks). The observed spontaneous tumor incidence for the XPA model after 9 months was comparable to that of wild-type mice (total 6%). For the XPA/p53 model, this was somewhat higher (9%/13% for males/females). The 3 positive control compounds used, B[a]P, p-cresidine, and 2-AAF, gave positive and consistent tumor responses in both the XPA and XPA/p53 model, but no or lower responses in wild-type mice. From the 13 ILSI compounds tested, the single genotoxic carcinogen (phenacetin) was negative in both the XPA and XPA/p53 model. Positive tumor responses were observed for 4 compounds, the immunosuppressant cyclosporin A, the hormone carcinogens DES and estradiol, and the peroxisome proliferator WY-14,643. Negative results were obtained with 5 other nongenotoxic rodent carcinogens, and 2 noncarcinogens tested. As expected, both DNA repair defi cient models respond to genotoxiccarcinogens. Combined with previous results, 6 out of 7 (86%) of the genotoxic human and/or rodent carcinogens tested are positive in the XPA model. The positive results obtained with the 4 mentioned nongenotoxicILSI compounds may point to other carcinogenic mechanisms involved, or may raise some doubts about their true nongenotoxicnature. In general, the XPA/p53 model appears to be more sensitive to carcinogens than the XPA model.

Keywords

Carcinogens carcinogenicity testing DNA repair genotoxic nucleotide excision repair short-term assay tumor suppressor gene xeroderma pigmentosum XPA.

References

Ames B.

Gold LS

( 1990). Too many rodent carcinogens: mitogenesis increases mutagenesis . Science249: 970—971.

Ando K.

Saitoh A.

Hino O.

Takahashi R.

Kimura M.

Katsuki M.

(1992). Chemically induced forestomach papillomas in transgenic mice carry mutant human c-H-ras transgenes. Cancer Res52: 978—982.

Blanchard KT

Barthel C.

French JE

Holden HE

Moretz R.

Pack FD

Tennant RW

Stoll R.

(1999). Transponder-inducedsarcoma in heterozygous p53+/-mouse. Toxicol Pathol27: 519—527.

Breuer M.

Slebos R.

Verbeek S.

Van Lohuizen M.

Wientjes E.

Berns A.

(1989). Very high frequency oflymphomainductionby a chemical carcinogen in pim-1 transgenic mice. Nature340: 61—63.

De Vries A.

Van Oostrom CTHM

Hofhuis FMA

Dortant PM

Berg RJW

De Gruijl FR

Wester PW

Van Kreijl CF

Capel PJA

Van Steeg H.

Verbeek S.

(1995). Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature377: 169—173.

Donehower LA

Harvey M.

Slagle BL

McArthur MJ

Montgomery CAJ

Butel JS

, et al. (1992). Mice defi cient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature356: 215—221.

Eastin WC

Haseman JK

Mahler JF

Bucher JR

(1998). The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens . Toxicol Pathol26: 461—473.

Fowlis DJ

Balmain A.

(1993). Oncogenes and tumor suppressor genes in transgenic mouse models of neoplasia. Eur J Cancer29A: 638—645.

Griesemer R.

Tennant RW

(1992). Transgenic mice in carcinogenicity testing. In: Mechanisms of Carcinogenesis in Risk Identification ,

Vaino H

Magee P

McGregor D

McMichael AJ

(eds). IARC, Lyon, France, pp.429—436.

10.

Harvey M.

McArthur MJ

Montgomery CAJ

Butel JS

Bradley A.

Donehower LA

(1993). Spontaneous and carcinogen-induced tumorigenesis in p53-defi cient mice. Nature5: 225—229.

11.

Hojo M.

Morimoto T.

Maluccio M.

Asano T.

Morimoto K.

Lagman M.

Shimbo T.

, SuthanthiranM (1999). Cyclosporineinduces cancer progression by a cell-autonomous mechanism. Nature397: 530—534.

12.

Jacks T.

Remington L.

Williams BO

Schmitt EM

Halachmi S.

Bronson RT

Weinberg RA

(1994). Tumor spectrum analysis in p53—mutant mice . Current Biol4: 1—7.

13.

Klein JC

Beems RB

Zwart PE

Hamzink M.

Zomer G.

Van Steeg H.

Van Kreijl CF

(2001). Intestinal toxicity and carcinogenic potential of the food mutagen 2-amino-1-methyl-6-phenylimidazo [4,5-b]-pyridine (PhIP) in DNA repair defi cient XPA -/- mice. Carcinogenesis22: 619—626.

14.

Leder A.

Kuo A.

Cardiff RD

Sinn E.

Leder P.

(1990). v-H-ras transgene abrogates the iniation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA87: 9178—9182.

15.

Mitsumori K.

Koizumi H.

Nomura T.

Yamamoto S.

(1998). Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol Pathol26: 520—531.

16.

Robinson D.

(1998). The international Life Sciences Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol Pathol26: 474—475.

17.

Saitoh A.

Kimura M.

Takahashi R.

Yokoyama M.

Nomura T.

Izawa M.

Sekiya T.

Nishimura S.

Katsuki M.

(1990). Most tumors in transgenic mice with human c-H-ras gene contained somatically activated transgenes. Oncogene5: 1195—1200.

18.

Spalding JW

Momma J.

Elwell MR

Tennant RW

(1993). Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-H-ras gene . Carcinogenesis14: 1335—1341.

19.

TennantRW

French JE

Spalding JW

(1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect103: 942—950.

20.

Tennant RW

Spalding J.

French JE

(1996) Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat Res365: 119—127.

21.

Van Kreijl CF

Van der Houven van Oordt CW

Kroese ED

Kryspin-Sorensen I.

Breuer ML

Storer, RD

(1998). Evaluation of the Eμ-pim-1 transgenic mouse model for short-term carcinogenicity testing. Toxicol Pathol26: 750—756.

22.

Van Kreijl CF

Van Steeg H.

(1998). Transgenic mouse models for the identifi cation of human carcinogens: A European perspective . Toxicol Pathol26:757—758.

23.

Van Lohuizen M.

Verbeek S.

Krimpenfort P.

Domen J.

Saris C.

Radaszkiewics T.

Berns A.

(1989). Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell56: 673—682.

24.

Van Oostrom CTHM

Boeve M.

Van den Berg J.

De Vries A.

Dollé MET

Beems RB

Van Kreijl CF

Vijg J.

Van Steeg H.

(1999). The effect of heterozygous loss of p53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-defi cient XPA mice. Environ Mol Mutagen34: 124— 130.

25.

Van Steeg H.

Klein JC

Beems RB

Van Kreijl CF

(1998). Use of DNA repair defi cient XPA transgenic mice in short-term carcinogenicity testing. Toxicol Pathol26: 742—749.

26.

Yamamoto S.

Mitsumori K.

Kodama Y.

Matsunuma N.

Manabe S.

Okamiya H.

Suzuki H.

Fukuda T.

Sakamaki Y.

Sunaga M.

Nomura G.

Hioki K.

Wakana S.

Nomura T.

Hayashi Y.

(1996). Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-H-ras gene, than in control non-transgenic mice. Carcinogenesis17: 2455—2461.